Table of Contents Author Guidelines Submit a Manuscript
Schizophrenia Research and Treatment
Volume 2014 (2014), Article ID 429291, 11 pages
http://dx.doi.org/10.1155/2014/429291
Research Article

Long-Term Risperidone Treatment Induces Visceral Adiposity Associated with Hepatic Steatosis in Mice: A Magnetic Resonance Approach

1Université Lille Nord de France, 59000 Lille, France
2Département de Pharmacologie Médicale, CHULille, EA 1046, 59000 Lille, France
3Inserm, U837, 59000 Lille, France
4IMPRT-IFR114, 59000 Lille, France
5Faculté de Pharmacie, 59006 Lille, France
6Inserm, U1011, 59000 Lille, France
7Institut Pasteur de Lille, 59019 Lille, France
8UArtois, 62300 Lens, France
9Laboratoire de Pharmacologie Médicale, EA 1046, Faculté de Médecine, Université Lille2, Pôle Recherche, 1 Place de Verdun, 59045 Lille Cedex, France

Received 28 July 2013; Accepted 3 April 2014; Published 27 April 2014

Academic Editor: Sonia Dollfus

Copyright © 2014 Florent Auger et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. de Hert, J. Detraux, R. van Winkel, W. Yu, and C. U. Correll, “Metabolic and cardiovascular adverse effects associated with antipsychotic drugs,” Nature Reviews Endocrinology, vol. 8, no. 2, pp. 114–126, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. J. A. Lieberman, T. S. Stroup, J. P. McEvoy et al., “Effectiveness of antipsychotic drugs in patients with chronic schizophrenia,” The New England Journal of Medicine, vol. 353, no. 12, pp. 1209–1223, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. W. W. Fleischhacker, R. D. McQuade, R. N. Marcus, D. Archibald, R. Swanink, and W. H. Carson, “A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia,” Biological Psychiatry, vol. 65, no. 6, pp. 510–517, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. C. U. Correll, J. M. Kane, and P. Manu, “Obesity and coronary risk in patients treated with second-generation antipsychotics,” European Archives of Psychiatry and Clinical Neuroscience, vol. 261, no. 6, pp. 417–423, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. K. G. M. M. Alberti and P. Zimmet, “Metabolic syndrome—a new world-wide definition. A consensus statement from the International Diabetes Federation,” Diabetic Medicine, vol. 23, no. 5, pp. 469–480, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Rasouli, B. Molavi, S. C. Elbein, and P. A. Kern, “Ectopic fat accumulation and metabolic syndrome,” Diabetes, Obesity and Metabolism, vol. 9, no. 1, pp. 1–10, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. B. J. Arsenault, E. P. Beaumont, J. P. Despres, and E. Larose, “Mapping body fat distribution: a key step towards the identification of the vulnerable patient?” Annals of Medicine, vol. 44, pp. 758–772, 2011. View at Google Scholar
  8. D. B. Carr, K. M. Utzschneider, R. L. Hull et al., “Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome,” Diabetes, vol. 53, no. 8, pp. 2087–2094, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. C. S. Fox, J. M. Massaro, U. Hoffmann et al., “Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study,” Circulation, vol. 116, no. 1, pp. 39–48, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. S. R. Smith, J. C. Lovejoy, F. Greenway et al., “Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity,” Metabolism, vol. 50, no. 4, pp. 425–435, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Tong, E. J. Boyko, K. M. Utzschneider et al., “Intra-abdominal fat accumulation predicts the development of the metabolic syndrome in non-diabetic Japanese-Americans,” Diabetologia, vol. 50, no. 6, pp. 1156–1160, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. J.-P. Després and I. Lemieux, “Abdominal obesity and metabolic syndrome,” Nature, vol. 444, no. 7121, pp. 881–887, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. A. S. Jackson and M. L. Pollock, “Steps towards the development of generalized equations for predicting body composition of adults,” Canadian Journal of Applied Sport Sciences, vol. 7, no. 3, pp. 189–196, 1982. View at Google Scholar · View at Scopus
  14. K. J. Ellis, “Human body composition: in vivo methods,” Physiological Reviews, vol. 80, no. 2, pp. 649–680, 2000. View at Google Scholar · View at Scopus
  15. S. Mattsson and B. J. Thomas, “Development of methods for body composition studies,” Physics in Medicine and Biology, vol. 51, no. 13, pp. R203–R228, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Abate, A. Garg, R. Coleman, S. M. Grundy, and R. M. Peshock, “Prediction of total subcutaneous abdominal, intraperitoneal, and retroperitoneal adipose tissue masses in men by a single axial magnetic resonance imaging slice,” American Journal of Clinical Nutrition, vol. 65, no. 2, pp. 403–408, 1997. View at Google Scholar · View at Scopus
  17. J. L. Lancaster, A. A. Ghiatas, A. Alyassin, R. F. Kilcoyne, E. Bonora, and R. A. DeFronzo, “Measurement of abdominal fat with T1-weighted MR images,” Journal of Magnetic Resonance Imaging, vol. 1, no. 3, pp. 363–369, 1991. View at Google Scholar · View at Scopus
  18. J. Kullberg, J. Brandberg, J.-E. Angelhed et al., “Whole-body adipose tissue analysis: comparison of MRI, CT and dual energy X-ray absorptiometry,” British Journal of Radiology, vol. 82, no. 974, pp. 123–130, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Berglund, L. Johansson, H. Ahlström, and J. Kullberg, “Three-point Dixon method enables whole-body water and fat imaging of obese subjects,” Magnetic Resonance in Medicine, vol. 63, no. 6, pp. 1659–1668, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Kvist, L. Sjostrom, and U. Tylen, “Adipose tissue volume determinations in women by computed tomography: technical considerations,” International Journal of Obesity, vol. 10, no. 1, pp. 53–67, 1986. View at Google Scholar · View at Scopus
  21. J. C. Seidell, C. J. G. Bakker, and K. van der Kooy, “Imaging techniques for measuring adipose-tissue distribution—a comparison between computed tomography and 1.5-T magnetic resonance,” American Journal of Clinical Nutrition, vol. 51, no. 6, pp. 953–957, 1990. View at Google Scholar · View at Scopus
  22. G. Brix, S. Heiland, M. E. Bellemann, T. Koch, and W. J. Lorenz, “MR imaging of fat-containing tissues: valuation of two quantitative imaging techniques in comparison with localized proton spectroscopy,” Magnetic Resonance Imaging, vol. 11, no. 7, pp. 977–991, 1993. View at Publisher · View at Google Scholar · View at Scopus
  23. B. H. Goodpaster, V. A. Stenger, F. Boada et al., “Skeletal muscle lipid concentration quantified by magnetic resonance imaging,” American Journal of Clinical Nutrition, vol. 79, no. 5, pp. 748–754, 2004. View at Google Scholar · View at Scopus
  24. F. Schick, J. Machann, K. Brechtel et al., “MRI of muscular fat,” Magnetic Resonance in Medicine, vol. 47, no. 4, pp. 720–727, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. E. L. Thomas, G. Hamilton, N. Patel et al., “Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study,” Gut, vol. 54, no. 1, pp. 122–127, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. H. H. Hu, K. S. Nayak, and M. I. Goran, “Assessment of abdominal adipose tissue and organ fat content by magnetic resonance imaging,” Obesity Reviews, vol. 12, no. 501, pp. e504–e515, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Ross, B. Goodpaster, D. Kelley, and F. Boada, “Magnetic resonance imaging in human body composition research. From quantitative to qualitative tissue measurement,” Annals of the New York Academy of Sciences, vol. 904, pp. 12–17, 2000. View at Google Scholar · View at Scopus
  28. S. B. Reeder, I. Cruite, G. Hamilton, and C. B. Sirlin, “Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy,” Journal of Magnetic Resonance Imaging, vol. 34, no. 4, pp. 729–749, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Wilhelm Poll, H.-J. Wittsack, J.-A. Koch et al., “A rapid and reliable semiautomated method for measurement of total abdominal fat volumes using magnetic resonance imaging,” Magnetic Resonance Imaging, vol. 21, no. 6, pp. 631–636, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. A. P. Levene, H. Kudo, M. J. Armstrong et al., “Quantifying hepatic steatosis—more than meets the eye,” Histopathology, vol. 60, no. 6, pp. 971–981, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. E. Lauressergues, F. Martin, A. Helleboid et al., “Overweight induced by chronic risperidone exposure is correlated with overexpression of the SREBP-1c and FAS genes in mouse liver,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 383, no. 4, pp. 423–436, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. P. A. Yushkevich, J. Piven, H. C. Hazlett et al., “User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability,” NeuroImage, vol. 31, no. 3, pp. 1116–1128, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. L. S. Szczepaniak, P. Nurenberg, D. Leonard et al., “Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population,” American Journal of Physiology—Endocrinology and Metabolism, vol. 288, no. 2, pp. E462–E468, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. R. Deslauriers, R. L. Somorjai, Y. Geoffrion, T. Kroft, I. C. Smith, and J. K. Saunders, “1H and 13C NMR studies of tissue from normal and diseased mice. Analysis of T1 and T2 relaxation profiles of triglycerides in liver,” NMR in Biomedicine, vol. 1, no. 1, pp. 32–43, 1988. View at Google Scholar · View at Scopus
  35. J. Ren, I. Dimitrov, A. D. Sherry, and C. R. Malloy, “Composition of adipose tissue and marrow fat in humans by 1H NMR at 7 Tesla,” Journal of Lipid Research, vol. 49, no. 9, pp. 2055–2062, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. N. A. Johnson, D. W. Walton, T. Sachinwalla et al., “Noninvasive assessment of hepatic lipid composition: advancing understanding and management of fatty liver disorders,” Hepatology, vol. 47, no. 5, pp. 1513–1523, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. S. F. Kim, A. S. Huang, A. M. Snowman, C. Teuscher, and S. H. Snyder, “Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 9, pp. 3456–3459, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Rodríguez-Arias, I. Broseta, M. A. Aguilar, and J. Miñarro, “Lack of specific effects of selective D1 and D2 dopamine antagonists vs. risperidone on morphine-induced hyperactivity,” Pharmacology Biochemistry and Behavior, vol. 66, no. 1, pp. 189–197, 2000. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Arnt, “Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine,” European Journal of Pharmacology, vol. 283, no. 1–3, pp. 55–62, 1995. View at Publisher · View at Google Scholar · View at Scopus
  40. H. E. Bays, “Adiposopathy: is “sick fat” a cardiovascular disease?” Journal of the American College of Cardiology, vol. 57, no. 25, pp. 2461–2473, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. I. R. Corbin, E. E. Furth, S. Pickup, E. S. Siegelman, and E. J. Delikatny, “In vivo assessment of hepatic triglycerides in murine non-alcoholic fatty liver disease using magnetic resonance spectroscopy,” Biochimica et Biophysica Acta, vol. 1791, no. 8, pp. 757–763, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Araya, R. Rodrigo, L. A. Videla et al., “Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease,” Clinical Science, vol. 106, no. 6, pp. 635–643, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. L. A. Videla, R. Rodrigo, J. Araya, and J. Poniachik, “Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease,” Free Radical Biology and Medicine, vol. 37, no. 9, pp. 1499–1507, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. J. H. Song, K. Fujimoto, and T. Miyazawa, “Polyunsaturated (n-3) fatty acids susceptible to peroxidation are increased in plasma and tissue lipids of rats fed docosahexaenoic acid-containing oils,” Journal of Nutrition, vol. 130, no. 12, pp. 3028–3033, 2000. View at Google Scholar · View at Scopus
  45. J. H. Song and T. Miyazawa, “Enhanced level of n-3 fatty acid in membrane phospholipids induces lipid peroxidation in rats fed dietary docosahexaenoic acid oil,” Atherosclerosis, vol. 155, no. 1, pp. 9–18, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. P. Puri, R. A. Baillie, M. M. Wiest et al., “A lipidomic analysis of nonalcoholic fatty liver disease,” Hepatology, vol. 46, no. 4, pp. 1081–1090, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. C. P. F. Marinangeli and P. J. H. Jones, “Functional food ingredients as adjunctive therapies to pharmacotherapy for treating disorders of metabolic syndrome,” Annals of Medicine, vol. 42, no. 5, pp. 317–333, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Sahebkar, “Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome?” Biofactors, vol. 39, no. 2, pp. 197–208, 2012. View at Google Scholar